By Ingrid Sassoon, Véronique Blanc (auth.), Laurent Ducry (eds.)
Antibody-drug conjugates (ADCs) characterize a promising healing procedure for melanoma sufferers by means of combining the antigen-targeting specificity of monoclonal antibodies (mAbs) with the cytotoxic efficiency of chemotherapeutic medicinal drugs. In Antibody-Drug Conjugates, professional researchers supply specific protocols for lots of of the foremost ADC options important for operating within the box. those chapters and methodologies are aimed toward the major initiatives essential to determine an appropriate goal, safely layout the mAb, the linker and the payload, in addition to to conjugate them in a reproducible and scalable style. Written within the hugely winning Methods in Molecular Biology™ layout, those distinctive chapters contain the type of sensible implementation recommendation that promises caliber results.
Authoritative and well timed, Antibody-Drug Conjugates goals to additional force ADC improvement and hence support towards bettering melanoma remedies of the future.
Read or Download Antibody-Drug Conjugates PDF
Similar oncology books
Views on melanoma Care is a distinct selection of insights from individuals, in line with their particular services and adventure. It presents a number views on melanoma care which can motivate the readers and inspire prime quality care via an better figuring out of the sufferers' wishes and the carers' abilities.
A CONCISE but THOROUGH review OF THE medicinal drugs AND ways utilized in melanoma CARE--BACKED by means of THE AUTHORITY OF HARRISON'S Harrison's handbook of Oncology is a carry-anywhere advisor to the care of sufferers with melanoma. more suitable through the newest released effects, this priceless scientific better half positive factors a variety of tables and succinct, outline-style textual content that places very important info at your fingertips.
Perry’s The Chemotherapy resource booklet, now in its 5th version, offers info at the collection of chemotherapeutic brokers, using mixture chemotherapy, and the toxicity of person drugs. geared up via website, this is often the single publication of its type to concentration strictly at the scientific perform of chemotherapy, and is intended to function a “one-stop store” for info on collection of chemotherapeutic brokers, therapy outlines, grading of unintended effects, and dose amendment.
- Plumer's principles & practice of infusion therapy
- WHO Classification of Tumours of the Central Nervous System
- Clinical Scenarios in Surgical Oncology
- Cachexia - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References
- Managing Cancer Breakthrough Pain
- Endocrine Neoplasia
Extra resources for Antibody-Drug Conjugates
If clinical exploration of ADC directed towards epithelial antigens has proven the value of the strategy, future ADC could also be directed towards vascular, stromal, and cancer stem cell targets [107–110]. In link with target expression features, progress of future ADC will require the capacity to better define the patient population which will benefit from the treatment. The development of improved companion diagnostics for the evaluation of target expression level and distribution in human tumor biopsies will be a critical asset.
Doronina SO, Toki BE, Torgov MY et al (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21:778–784 25. Erickson HK, Widdison WC, Mayo MF et al (2010) Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody–maytansinoid conjugates. Bioconjug Chem 21:84–92 26. Kellogg BA, Garrett L, Kovtun Y et al (2011) Disulfide-linked antibody–maytansinoid 23 conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage.
Sanderson RJ, Hering MA, James SF et al (2005) In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res J Am Assoc Cancer Res 11:843–852 30. Hamblett KJ, Senter PD, Chace DF et al (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res J Am Assoc Cancer Res 10:7063–7070 31. Shen B, Xu K, Liu L et al (2012) Conjugation site modulates the in vivo stability and therapeutic activity of antibody–drug conjugates.
Antibody-Drug Conjugates by Ingrid Sassoon, Véronique Blanc (auth.), Laurent Ducry (eds.)